Clinical utility of tissue polypeptide antigen determination in lung cancer management

Lung Cancer ◽  
1995 ◽  
Vol 13 (3) ◽  
pp. 332
Keyword(s):  
Lung Cancer ◽  
Clinical Utility ◽  
Tissue Polypeptide Antigen ◽  
Cancer Management ◽  
Antigen Determination

scholarly journals Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 103
Author(s):  
Maarten J. IJzerman ◽  
Jasper de Boer ◽  
Arun Azad ◽  
Koen Degeling ◽  
Joel Geoghegan ◽  
...  
Keyword(s):  
Clinical Utility ◽  
Clinical Laboratory ◽  
Genomic Analysis ◽  
Current Evidence ◽  
Liquid Biopsies ◽  
Blood Draw ◽  
Minimum Quality Standards ◽  
Cancer Management ◽  
Alternative Funding ◽  
And Performance

Blood-based liquid biopsies are considered a new and promising diagnostic and monitoring tool for cancer. As liquid biopsies only require a blood draw, they are non-invasive, potentially more rapid and assumed to be a less costly alternative to genomic analysis of tissue biopsies. A multi-disciplinary workshop (n = 98 registrations) was organized to discuss routine implementation of liquid biopsies in cancer management. Real-time polls were used to engage with experts’ about the current evidence of clinical utility and the barriers to implementation of liquid biopsies. Clinical, laboratory and health economics presentations were given to illustrate the opportunities and current levels of evidence, followed by three moderated break-out sessions to discuss applications. The workshop concluded that tumor-informed assays using next-generation sequencing (NGS) or PCR-based genotyping assays will most likely provide better clinical utility than tumor-agnostic assays, yet at a higher cost. For routine application, it will be essential to determine clinical utility, to define the minimum quality standards and performance of testing platforms and to ensure their use is integrated into current clinical workflows including how they complement tissue biopsies and imaging. Early health economic models may help identifying the most viable application of liquid biopsies. Alternative funding models for the translation of complex molecular diagnostics, such as liquid biopsies, may also be explored if clinical utility has been demonstrated and when their use is recommended in multi-disciplinary consensus guidelines.

scholarly journals Recent advances in the management of non-small cell lung cancer

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 2110 ◽  
Author(s):  
Samira Shojaee ◽  
Patrick Nana-Sinkam
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Surgical Approaches ◽  
Small Cell Lung ◽  
Cancer Management ◽  
Recent Advances ◽  
Improved Outcomes ◽  
Significant Step

Lung cancer is the number one cause of cancer-related death in both men and women. However, over the last few years, we have witnessed improved outcomes that are largely attributable to early detection, increased efforts in tobacco control, improved surgical approaches, and the development of novel targeted therapies. Currently, there are several novel therapies in clinical practice, including those targeting actionable mutations and more recently immunotherapeutic agents. Immunotherapy represents the most significant step forward in eradicating this deadly disease. Given the ever-changing landscape of lung cancer management, here we present an overview of the most recent advances in the management of non-small cell lung cancer.

scholarly journals Paradigm shift in the management of metastatic Non-small Cell Lung Cancer

2021 ◽  
Author(s):  
Ruby Gupta ◽  
Melanie Smalley ◽  
Nwabundo Anusim ◽  
Vishal Jindal ◽  
Mandeep Singh Rahi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Paradigm Shift ◽  
Survival Rates ◽  
Small Cell ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Cancer Management ◽  
Chemotherapeutic Approach

Background: Lung cancer is one of the leading causes of cancer mortality in the US. The use of precision medicine in the past 10 years has significantly changed the therapeutic landscape of lung cancer. Management of advanced non-small cell lung cancer (NSCLC) has transitioned from a chemotherapeutic approach to targeted treatments and immunotherapeutic agents. Several tyrosine kinase inhibitors (TKIs) have been approved for patients with targeted mutations while patients who do not have driver mutations; immunotherapy has been recently approved as frontline therapy, which has resulted in marked improvement in overall survival and added a new tool in our armamentarium. Aims: The purpose of this review is to highlight recent advancements in diagnostic approach and management strategies in patients with metastatic NSCLC. Materials and methods: Published studies included in Medline (via PubMed) and National Comprehensive Cancer Network Guidelines were reviewed for data gathering. Conclusion: The use of next generation sequencing has significantly changed our understanding of molecular oncogenic mechanisms of lung cancer. These advancements have created a paradigm shift in the treatment strategies of metastatic lung cancer from primarily chemotherapeutic approach to increasing use of targeted therapies and immune check point inhibitors (ICI) leading to better survival rates and lesser toxicity.

scholarly journals Liposomal drug delivery system as an effective treatment approach for lung cancer

2020 ◽  
Vol 10 (3-s) ◽  
pp. 367-370
Author(s):  
Kinjal Patel ◽  
Devanshi Patel
Keyword(s):  
Lung Cancer ◽  
Drug Delivery ◽  
Drug Loading ◽  
Chemotherapeutic Agents ◽  
The Body ◽  
Therapeutic Interventions ◽  
Target Delivery ◽  
Liposomal Drug ◽  
Cancer Management ◽  
Important Field

Worldwide, cancer is one of the leading causes of mortality and cancer rates are set to increase at alarming rate globally. There are various types of cancer in which the leading type is the lung cancer.   In recent years lipid-based carriers, such as liposomes, have successfully encapsulated chemotherapeutic agents ameliorating some toxicity issues, while enhancing the overall therapeutic activity in cancer patients. In addition to this, nanomaterials can help to improved half-life in the body, morphology, for increased drug loading and many other ways. The survey discussed in this review will lead the anticancer therapy and cancer management which will provide the platform to the next generation.  Therefore, this critical review includes the therapeutic interventions, liposomes target delivery, active and passive drug loading. Finally, we attempt to summarize the current challenges in nanotherapeutics and provide an outlook on the future of this important field. Keywords: Drug Delivery, Liposomes target Delivery, Nanostructures, Drug loading

Sign in / Sign up

Export Citation Format

Share Document